Nov 12
Midcap Short holds up to 4 mid caps above $2B short. Selection follows the model's negative score. Returns are those of a short position in the basket, so the figure rises when the basket falls.
Equal capital goes into every position. The book is rebuilt each morning from the names the model expects to fall, and the orders are placed as market orders, so shorts and covers fill at the opening price. Positions are held for 12 to 28 days: they are not rotated out before day 12 and are covered by day 28. Every position carries a 40% stop on both sides. A short is covered if the price runs 40% above its entry, and equally if it falls 40% below it, filling at the first open after the level is touched. Reported returns are those of a short position in the basket: the position gains when the basket falls and loses when it rises. They are measured from those opening prices and include every stop exit. A short position's loss is not capped, and borrowing costs and stock-loan fees are not included.
B.Riley lifted its price target to $37 from $25 (over 100% upside from $18.08), citing the Corsicana lease as the most robust it has seen in the space given scale, capital intensity, and record-high yield on cost. The firm noted RIOT trades at a ~16% implied cap rate versus peers at 11%, suggesting valuation re-rating potential.
Investing.comH.C. Wainwright maintained a Buy rating and $65 price target post-Q3, well above the ~$20 trading level. The reiteration offers a modest counterweight to the selloff but is unlikely to reverse sentiment on its own.
Investing.comBeam reported that risto-cel met the primary efficacy endpoint (freedom from severe VOCs for 12 consecutive months) and all primary safety and secondary endpoints in the BEACON Phase 1/2 trial. This de-risks the lead program and supports an imminent BLA submission, a key value-inflection catalyst for the stock.
Beam Therapeutics Press Release (GlobeNewswire)Beam reiterated plans to submit a U.S. BLA for risto-cel to the FDA as early as end of 2026. The filing is a near-term regulatory catalyst that could drive re-rating as it approaches and upon acceptance.
Beam Therapeutics Press Release (GlobeNewswire)Beam will present earlier-cutoff BEACON data in an oral presentation at the ASH Annual Meeting (Dec 12-15, 2026). This is a near-term event that could provide additional durability/safety detail and move the stock depending on reception.
Beam Therapeutics Press Release (GlobeNewswire)Jefferies upgraded RIOT to Buy from Hold and doubled its price target to $28 from $13, while JPMorgan raised its PT to $28 from $22 maintaining Overweight. Both cited attractive risk-adjusted economics of the Corsicana powered land lease, with Jefferies noting it lets RIOT monetize the site with less execution and financing risk. Stock rose ~2% pre-market on the news.
Yahoo FinanceLegend reported Q3 2026 revenue of $359.5M (slightly above consensus) but a GAAP loss per share of $0.13 versus an expected near-breakeven, reversing Q2's first-ever profit. Shares fell roughly 10-16% as investors refocused on profitability durability; the miss is the dominant near-term price driver.
Investing.comOn the Q3 call, CFO Carlos Santos said Wall Street's 2027 Carvykti sales consensus sits at the "higher end" of internal scenarios, citing ex-U.S. launch delays and slower earlier-line U.S. share growth amid bispecific competition. The cautious forward tone compounds the earnings miss and pressures near-term estimates.
FiercePharmaQ3 release highlighted five-year CARTITUDE-2 Cohort A data (50% alive and progression-free off further treatment) and updated NCCN guidelines favoring CAR-T at first relapse, plus FDA IND clearance for LB2501 in vivo CAR-T. These support the long-term thesis but are secondary to near-term earnings concerns.
GlobeNewswire (Company Press Release)Grab signed joint development agreements with SoftBank and PETROS for $1.85B initial seed capital ($750M from Grab) to build AI infrastructure in Malaysia, targeting 5GW+ of AI compute. The agreements carry binding funding obligations, and shares fell 3.2% on the news as investors weighed the capital outlay against Grab's core business. SoftBank's five-year lock-up on its direct Grab shares is a modest offset.
SEC Filing (Form 6-K)RIOT reported Q3 revenue of $181.4M and EPS of $0.01 versus analyst expectations of a $0.36 loss on $160.8M revenue, and announced a 15-year triple-net powered land lease with a leading Frontier AI Lab for its entire Corsicana campus (910 MW, ~$28B total contract value, ~$1.8B average annual rent). Shares jumped ~15% on the day; the deal materially shifts RIOT's valuation toward AI data center infrastructure and the company stated it does not anticipate issuing equity to fund projects.
Riot Platforms Press ReleaseBeam reported a Q3 2026 net loss of $134.4 million ($1.28/share) on revenue of $307,000, with $1.0 billion in cash and runway into mid-2029. The update also highlighted BEAM-302 pivotal dosing completion expected in H1 2027 and BEAM-301 proof-of-concept data, framing the broader pipeline narrative.
Beam Therapeutics Q3 2026 ResultsGrab reported Q3 2026 revenue of $1,112M (+27% YoY, +30% constant currency) and record Adjusted EBITDA of $237M (+73% YoY), with profit of $18M. Full-year 2026 revenue guidance was raised to $4.15–4.20B and Adjusted EBITDA to $790–800M. The beat-and-raise plus $400M of September–October buybacks ($500M remaining) is a positive near-term sentiment driver.
SEC Filing (Q3 2026 Earnings Press Release)Taiwan's Fair Trade Commission rejected Grab's proposed acquisition of Delivery Hero's foodpanda Taiwan business, forcing a $60M break fee to be recorded in Q4 2026. The charge is excluded from Adjusted EBITDA and does not affect full-year guidance, but removes a growth catalyst and adds a one-time IFRS earnings hit.
SEC Filing (Q3 2026 Earnings Press Release)Beam reported initial BEAM-301 Phase 1/2 data showing dose-dependent improvements in fasting tolerance and elimination of starch supplementation in two of three 40 mg patients, with a 60 mg cohort enrolling and FDA engagement planned. Positive but earlier-stage, it supports pipeline optionality.
Beam Therapeutics Press Release